With the model of HH + STIA, we recapitulate specific features of RA patients—as presented in the introduction—and provide proof of concept that selective agonists at FPR2 can offer a therapeutic opportunity, not only to control joint disease but also control the onset of secondary organ injuries which, in patients, represent a major comorbidity and can be lethal. The gene discussed is FPR2; the disease is rheumatoid arthritis.